Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy

Annals of Surgery

Volumn 263, Issue 1, 2016, Pages 96-102

  Lee, Choong Kun ^a   Jung, Minkyu ^a   Jung, Inkyung ^b   Heo, Su Jin ^a   Jeong, Yong Hyu ^b   An, Ji Yeong ^a   Kim, Hyoung Il ^a   Cheong, Jae Ho ^a   Hyung, Woo Jin ^a   Noh, Sung Hoon ^a   Kim, Hyo Song ^a   Rha, Sun Young ^a   Chung, Hyun Cheol ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Diabetes mellitus; Gastric cancer; Metformin; Survival benefit

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN; MEGLITINIDE; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CLINICAL EVALUATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COVARIANCE; DIABETIC PATIENT; DRUG USE; FEMALE; FOLLOW UP; GASTRECTOMY; HAZARD RATIO; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL RATE; TREATMENT DURATION; COMPARATIVE STUDY; COMPLICATION; DIABETES COMPLICATIONS; MORTALITY; RETROSPECTIVE STUDY; STOMACH NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DIABETES COMPLICATIONS; FEMALE; GASTRECTOMY; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84953839826     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001086     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Gallo A, Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol. 2006;12:3237-3242.
3. Jung KW, Won YJ, Kong HJ, et al. Survival of Korean adult cancer patients by stage at diagnosis, 2006-2010: national cancer registry study. Cancer Res Treat. 2013;45:162-171.
4. Dailey G. Overall mortality in diabetes mellitus: where do we stand today? Diabetes Technol Ther. 2011;13(suppl 1):S65-S74.
5. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60:207-221.
6. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-841.
7. Ge Z, Ben Q, Qian J, et al. Diabetes mellitus and risk of gastric cancer: a systematic review and meta-analysis of observational studies. Eur J Gastroenterol Hepatol. 2011;23:1127-1135.
8. Coughlin SS, Calle EE, Teras LR, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160-1167.
9. Lee MS, Hsu CC, Wahlqvist ML, et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800, 000 individuals. BMC Cancer. 2011;11:20.
10. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304-1305.
11. Dowling RJ, Niraula S, Stambolic V, et al. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48:R31-R43.
12. Landman GW, Kleefstra N, Van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010;33:322-326.
13. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinasedependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269-10273.
14. Quinn BJ, Kitagawa H, Memmott RM, et al. Repositioningmetformin for cancer prevention and treatment. Trends Endocrinol Metab. 2013;24:469-480.
15. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27:3297-3302.
16. Margel D, Urbach DR, Lipscombe LL, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol. 2013;31:3069-3075.
17. Lee JH, Kim TI, Jeon SM, et al. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2012;131:752-759.
18. Rieken M, Xylinas E, Kluth L, et al. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol. 2014;40:113-120.
19. Rieken M, Xylinas E, Kluth L, et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscleinvasive bladder cancer. BJU Int. 2013;112:1105-1112.
20. Kato K, Gong J, Iwama H, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther. 2012;11:549-560.
21. Kim YI, Kim SY, Cho SJ, et al. Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. Aliment Pharmacol Ther. 2014;39:854-863.
22. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
23. Kwon Y, Abdemur A, Lo Menzo E, et al. The foregut theory as a possible mechanism of action for the remission of type 2 diabetes in low body mass index patients undergoing subtotal gastrectomy for gastric cancer. Surg Obes Relat Dis. 2014;10:235-242.
24. An JY, Kim YM, Yun MA, et al. Improvement of type 2 diabetes mellitus after gastric cancer surgery: short-term outcome analysis after gastrectomy. World J Gastroenterol. 2013;19:9410-9417.
25. Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507-7511.
26. Tapia O, Riquelme I, Leal P, et al. The PI3K (AKT (mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch. 2014;465:25-33.
27. Johnson JA, Carstensen B, Witte D, et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia. 2012;55:1607-1618.
28. Takahari D, Yamada Y, Okita NT, et al. Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology. 2009;76:42-48.
29. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009;119:2051-2057.